Rezolute (RZLT) Interest Expenses (2012 - 2019)
Rezolute recorded quarterly Interest Expenses of $4.3 million in Q2 2019, down 27.16% quarter-over-quarter from $5.9 million in Q1 2019, and up 576.3% year-over-year from $635490.0 in Q2 2018.
Rezolute's Interest Expenses history runs 8 years deep, the most recent figure standing at $4.3 million for Q2 2019.
- In Q2 2019, Interest Expenses rose 576.3% year-over-year to $4.3 million; the TTM figure through Mar 2020 stood at $4.3 million (down 50.79% YoY), while the FY2021 annual figure was $375000.0, changed N/A from the prior year.
- Interest Expenses came in at $4.3 million for Q2 2019 at Rezolute, down from $5.9 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $5.9 million in Q1 2019 to a low of $147.0 in Q4 2017.
- A 5-year average of $935455.3 and a median of $1965.0 in 2015 frame the typical range for Interest Expenses.
- Across the five-year window, Interest Expenses sank 99.94% in 2015 and surged 876090.48% in 2018, its largest moves.
- Rezolute's Interest Expenses stood at $1379.0 in 2015, then grew by 15.66% to $1595.0 in 2016, then sank by 90.78% to $147.0 in 2017, then soared by 876090.48% to $1.3 million in 2018, then soared by 233.68% to $4.3 million in 2019.
- According to Business Quant data, Interest Expenses over the past three periods registered $4.3 million, $5.9 million, and $1.3 million for Q2 2019, Q1 2019, and Q4 2018 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 4.30 Mn |
| Jun 30, 2019 | 4.30 Mn |
| Mar 31, 2019 | 5.90 Mn |
| Mar 31, 2019 | 5.90 Mn |
| Dec 31, 2018 | 1.29 Mn |
| Dec 31, 2018 | 1.29 Mn |
| Sep 30, 2018 | 911,000.00 |
| Sep 30, 2018 | 911,000.00 |
| Jun 30, 2018 | 635,490.00 |
| Jun 30, 2018 | 635,490.00 |
| Mar 31, 2018 | 53,363.00 |
| Mar 31, 2018 | 53,363.00 |
| Dec 31, 2017 | 147.00 |
| Dec 31, 2017 | 147.00 |
| Sep 30, 2016 | 1,595.00 |
| Sep 30, 2016 | 1,595.00 |
| Jun 30, 2016 | 904.00 |
| Jun 30, 2016 | 904.00 |
| Mar 31, 2016 | 1,143.00 |
| Mar 31, 2016 | 1,143.00 |
| Dec 31, 2015 | 1,379.00 |
| Dec 31, 2015 | 1,379.00 |
| Sep 30, 2015 | 1,613.00 |
| Sep 30, 2015 | 1,613.00 |
| Jun 30, 2015 | 1,844.00 |
| Jun 30, 2015 | 1,844.00 |
| Mar 31, 2015 | 2,086.00 |
| Mar 31, 2015 | 2,086.00 |
| Dec 31, 2014 | 2,299.00 |
| Dec 31, 2014 | 2,299.00 |
| Sep 30, 2014 | 500.00 |
| Sep 30, 2014 | 500.00 |
| Jun 30, 2014 | 500.00 |
| Jun 30, 2014 | 500.00 |
| Mar 31, 2014 | 3.44 Mn |
| Mar 31, 2014 | 3.44 Mn |
| Dec 31, 2013 | 623,347.00 |
| Dec 31, 2013 | 623,347.00 |
| Sep 30, 2013 | 164,817.00 |
| Sep 30, 2013 | 164,817.00 |
| Jun 30, 2013 | 172,837.00 |
| Jun 30, 2013 | 172,837.00 |
| Mar 31, 2013 | 181,703.00 |
| Mar 31, 2013 | 181,703.00 |
| Dec 31, 2012 | 109,421.00 |
| Dec 31, 2012 | 109,421.00 |
| Sep 30, 2012 | 104,898.00 |
| Sep 30, 2012 | 104,898.00 |
| Jun 30, 2012 | 194,744.00 |
| Jun 30, 2012 | 194,744.00 |
| Mar 31, 2012 | 91,735.00 |
| Mar 31, 2012 | 91,735.00 |